Aim: To estimate the frequency of metabolic syndrome and insulin resistance in patients of chronic plaque psoriasis and to evaluate their association with psoriasis severity.

Materials and Method: 110 patients aged 18–70 years with chronic plaque psoriasis were included in the study. Patients were subjected to blood testing for serum lipid profile, fasting blood glucose and fasting insulin level. Metabolic syndrome was diagnosed according to the NCEP ATP III criteria. Psoriasis severity was classified as mild or moderate to severe according to Psoriasis Area Severity Index (PASI) and body surface area (BSA). When PASI was ≥10 and BSA was >10, psoriasis was designated as moderate to severe.

Results: The prevalence of metabolic syndrome was 42.7% and prevalence of insulin resistance was 43.6%. Mean values for all variables anthropometric measurements, age and Extent of disease were higher in patients with metabolic syndrome as compared to those without metabolic syndrome and this difference was statistically significant. 28.2% of participants had increased Total cholesterol level, 21.8% of participants had increased LDL levels, 47.3% of participants had increased VLDL levels, 48.2% of participants had increased triglycerides level and 30% had reduced HDL levels. The mean triglyceride level was raised in participants (177.6 + 102.2) and mean HDL levels were within normal limits (47.3 + 13).

Conclusion: Chronic plaque psoriasis should not be regarded merely as a cutaneous disorder but as a systemic inflammatory condition with significant metabolic implications. Early identification and management of metabolic syndrome and insulin resistance in psoriatic patients can aid in reducing long-term cardiovascular morbidity and improving overall patient outcomes.